AVI Polymers (539288)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Price-to-book of 1.13: market price ₹11.17 is close to book value ₹9.87, offering limited cushion if book value is trustworthy.
• ROCE of 19.42% suggests decent operating returns on capital employed.
• Piotroski F-Score of 6/9 points to reasonable overall financial health.
• Recent profit growth of 1,000% from a low base, with PEG of 0.02, shows momentum—though it must be treated skeptically.
• D/E is N/A; if the company is truly debt-free, that would be a positive, but data is unclear.

Concerns

• Critical data inconsistency: market cap of ₹5 Cr, P/E of 18.66, ROE of 205.13%, and quarterly net profit of ₹7 Cr cannot all be simultaneously correct.
• Sales growth is 0.00%; profit growth appears driven by margins or a low base rather than a scalable franchise.
• Microcap status with ₹5 Cr market cap, no dividend, and promoter holding undisclosed raises governance and liquidity risks.
• 52-week range ₹7.93–₹34.57 means the stock has fallen sharply; it may be a value trap rather than a bargain.

AI Analysis

Very little about AVI Polymers passes my first test—I need to understand a business before I can value it. At ₹11.17, the entire company is priced at only ₹5 crore, barely above its book value of ₹9.87 per share. On the surface, a P/B of 1.13 offers a margin of safety, and ROCE of 19.42% is decent. But the other numbers do not add up. A P/E of 18.66 with a ₹5 crore market cap implies trailing net profit of roughly ₹0.27 crore; that would make ROE about 6%, not the reported 205.13%. The latest quarter allegedly shows ₹132 crore sales and ₹7 crore profit—that alone would justify a market cap many times this one. I cannot reconcile these figures, and when financial statements contradict themselves, I move on. The 1,000% profit growth sounds exciting, but sales growth is 0%. This is not a growing franchise; it is a margin rebound from a very low base. Specialty chemicals can be decent, but this is a microcap with no dividend, unknown promoter holding, and a 52-week range of ₹7.93 to ₹34.57. The stock has fallen from over ₹34 to ₹11, reminding me that small prices can become smaller. Piotroski’s 6/9 is mildly encouraging, but it does not overcome the governance and data red flags. I would demand far more audited history, cash flow statements, and a proven competitive moat before deploying capital. At best it is a speculative turnaround; at worst it is a value trap. In Graham’s language, price is what you pay, value is what you get—and here value cannot be estimated with the figures given.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer